SYRE · Spyre Therapeutics Inc
Price
Snapshot
50 fields| Market Cap | $8.87B |
| P/E | — |
| Float | — |
| Beta | 2.95 |
| Volatility | 73.8% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | — |
| Price | 90.36 |
| Change | +0.00% |
| Prev Close | 90.36 |
| Open | 100.56 |
| Day Low | 98.79 |
| Day High | 103.57 |
| Avg Vol | 1 |
| Avg $ Vol | $115.8M |
| 52W High | 108.92 |
| 52W Low | 14.51 |
| 52W Pos | 80.3% |
| From High | −17.04% |
| From Low | +522.96% |
| Max DD 1Y | −14.06% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −12.50% |
| SMA 50 | −8.18% |
| SMA 200 | +50.54% |
| RSI (14) | 38.9 |
| Vol 30D | 63.3% |
| Vol 90D | 66.9% |
| 1Y Range | 15–109 |
| Daily bars | 501 |
| Perf Week | −13.15% |
| Perf Month | −4.35% |
| Perf Quarter | +29.82% |
| Perf Half Y | +116.95% |
| Perf Year | +448.74% |
| Perf YTD | +195.49% |
| Prev Day | +0.00% |
| Clavix | — |
| Debt / Eq | 0.00 |
| Curr Ratio | 13.25 |
| Int Cover | -2.1× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | — |
Against Biotechnology
36 companies| Metric | SYRE | Sector spread | Median |
|---|---|---|---|
| Beta | 2.95 | 0.48 | |
| Volatility | 73.8% | 12.2% | |
| Debt / equity | 0.00 | 0.24 | |
| Current ratio | 13.25 | 3.73 | |
| Interest coverage | -2.1× | -0.2× |
Recent news
5 most recent · click to openMizuho raised its price target on Spyre Therapeutics (NASDAQ:SYRE) from $84.00 to $120.00 and issued an 'outperform' rating in a research note on Monday.
The article frames Spyre Therapeutics' stock outlook as dependent on upcoming 2026 study catalysts, with the investment thesis hinging on whether its broad IBD pipeline can deliver meaningful clinical proof-of-concept data. The article body provides limited additional detail beyond this thesis statement.
Abivax, Definium Therapeutics, Danaher, argenex, Apogee Therapeutics, Spyre Therapeutics, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies in the biotechnology industry that develop products or technologies based on biological processes, such as drugs, therapies, diagnostics, or medical research tools. For […]
Spyre Therapeutics director Michael Thomas Henderson sold 20,000 shares of company stock at an average price of $100.00 per share on June 22nd, for a total transaction value of $2,000,000, leaving him with 68,606 shares.
Spyre Therapeutics reported positive ulcerative colitis data for two of its IBD candidates, SPY-001 and SPY-002, drawing positive analyst reactions.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | B | $9.34B | 119.77 | 1.49 |
| TWST | Twist Bioscience Corp | D+ | $9.44B | — | 2.25 |
| TGTX | TG Therapeutics Inc | B- | $8.26B | 16.62 | 1.80 |
| CYTK | Cytokinetics Inc | B | $10.06B | — | 0.35 |
| IONS | Ionis Pharmaceuticals Inc | B- | $10.12B | — | 0.33 |
| KRYS | Krystal Biotech Inc | B | $10.40B | 40.23 | 0.48 |
| CAI | Caris Life Sciences Inc | C | $7.25B | 59.62 | 0.44 |
| CGON | CG Oncology Inc | B- | $6.59B | — | 0.19 |
You just read one holding. Clavix reads the whole portfolio.
Connect or type in what you own and every position is graded on the same five areas as SYRE — with the ones that changed today at the top.